Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

<p>Supplementary video 2</p>

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awdur:	Min Wei (16918572) (author)
Awduron Eraill:	Xinping Huang (16918575) (author), Liming Liao (16918578) (author), Yonglu Tian (16918581) (author), Xiaofeng Zheng (16918584) (author)
Cyhoeddwyd:	2025
Pynciau:	Cancer Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biochemistry Protein/protein interactions Biomarkers Protein biomarkers Carcinogenesis DNA damage and repair DNA Damage and Repair Drug Resistance Regulation of gene expression in drug resistance Gastrointestinal Cancers Colorectal cancer Oncogenes & Tumor Suppressors Oncogenes Progression, Invasion & Metastasis
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
gan: Min Wei (16918572)
Cyhoeddwyd: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
gan: Kavya Ramkumar (16474203)
Cyhoeddwyd: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
gan: Craig M. Goodwin (14955973)
Cyhoeddwyd: (2025)

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
gan: Marta J. Llorca-Cardenosa (14961612)
Cyhoeddwyd: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
gan: Marta J. Llorca-Cardenosa (14961612)
Cyhoeddwyd: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
gan: Marta J. Llorca-Cardenosa (14961612)
Cyhoeddwyd: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
gan: Marta J. Llorca-Cardenosa (14961612)
Cyhoeddwyd: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
gan: Marta J. Llorca-Cardenosa (14961612)
Cyhoeddwyd: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
gan: Sanna Pikkusaari (15055802)
Cyhoeddwyd: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
gan: Sanna Pikkusaari (15055802)
Cyhoeddwyd: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
gan: Long Jiang (14956159)
Cyhoeddwyd: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
gan: Long Jiang (14956159)
Cyhoeddwyd: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
gan: Long Jiang (14956159)
Cyhoeddwyd: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
gan: Katrina M. Lappin (9340394)
Cyhoeddwyd: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
gan: Katrina M. Lappin (9340394)
Cyhoeddwyd: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
gan: Katrina M. Lappin (9340394)
Cyhoeddwyd: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
gan: Katrina M. Lappin (9340394)
Cyhoeddwyd: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
gan: Sami Belhadj (15052341)
Cyhoeddwyd: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
gan: Arun Kanakkanthara (14937731)
Cyhoeddwyd: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
gan: Arun Kanakkanthara (14937731)
Cyhoeddwyd: (2025)

Cannot write session to /tmp/vufind_sessions/sess_bll3649b8ahk03oac71o4qnj08